CytoMed Therapeutics
Singapore
About CytoMed Therapeutics
CytoMed Therapeutics is a spin-off from Singapore's Agency for Science, Technology, and Research (A*Star) that focuses on turning its patented technology into "off-the-shelf" immunotherapeutics based on gamma delta () T cells and natural killer (NK) cells treating a variety of tumors. CytoMed also generates induced pluripotent stem cells (iPSCs) and develops them into cellular medicines for its customers utilizing patented technology.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $1.1M
- Funding stage: IPO
- Last round: Series Unknown (Jan 2020)
- Ticker: nasdaq:GDTC
- Website: cytomed.sg
- Phone: +65 9732 8844
Industries & Categories
Biotechnology
Social Profiles
Canonical: https://fsome.com/organization/cytomed-therapeutics-86821 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.